SEC Comment Letter for CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — Feb 12, 2018
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: Feb. 12, 2018 · CIK: 0001053691 · Accession: 0000000000-18-004839
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222879
Letter
February 12, 2018 David Kalergis Chief Executive Officer Diffusion Pharmaceuticals Inc. 1317 Carlton Avenue, Suite 200 Charlottesville, VA 22902 Re:Diffusion Pharmaceuticals Inc. Registration Statement on Form S-3 Filed February 6, 2018 File No. 333-222879 Dear Mr. Kalergis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: David Rosenthal
Show Raw Text
February 12, 2018
David Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals Inc.
1317 Carlton Avenue, Suite 200
Charlottesville, VA 22902
Re:Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed February 6, 2018
File No. 333-222879
Dear Mr. Kalergis:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: David Rosenthal